Ensysce Biosciences, Inc. filed a Form D with the Securities and Exchange Commission on 2026-08-20.
Ensysce Biosciences, Inc. filed a Form D notice of an exempt securities offering with the SEC on August 20, 2026. Ensysce Biosciences, Inc. trades on Nasdaq as ENSC; it was formerly Leisure Acquisition Corp. The filing reports $77.20M sold. Its industry group is Other Health Care. It names D Kirkpatrick (Executive Officer, Director), Bob Gower (Director), William Chang (Director) (SEC Form D, August 20, 2026).
In its own words: “En + Cy is pioneering small molecule therapies that treat chronic pain by targeting its root cause via the central nervous system.” (ensysce.com, checked November 8, 2026)
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Ensysce Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-08-20 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Ensysce Biosciences, Inc.
Free to see. No signup.
More on the people and the money behind Ensysce Biosciences, Inc., from the filings we hold.
Other Health Care raises by companies based in California, filed in August 2026, largest first.
Get an email when Ensysce Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Ensysce Biosciences, Inc. raises, hires or launches. No email unless you switch it on.
Watch Ensysce Biosciences, Inc. →Get the full cited report on Ensysce Biosciences, Inc.
What the filing shows about Ensysce Biosciences, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ensysce Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Ensysce Biosciences, Inc.'s address as 7946 Ivanhoe Ave,, Suite 201, La Jolla, CA 92037.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Ensysce Biosciences, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Ensysce Biosciences, Inc. See pricing
Ensysce Biosciences, Inc. is a registered filer with the SEC (CIK 1716947) and has filed since 2023-03-01. 6 filings are on record, the latest on 2026-08-20.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Ensysce Biosciences, Inc.'s Form D of 2026-08-20 names D Kirkpatrick, Bob Gower, William Chang and 4 more as its officers, directors or promoters.
Its new offerings report $93.10M sold across 6 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 866 filings in Other Health Care, totalled by week. The dot is this raise, $77.20M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
Ensysce Biosciences, Inc. is a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the fear of and the potential for opioid misuse, abuse and overdose. Our current development pipeline…
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
D Kirkpatrick is named as Executive Officer and Director on the Form D that Ensysce Biosciences, Inc. filed with the SEC on 20 August 2026, one of 7 people that filing names.
Bob Gower is named as Director on the Form D that Ensysce Biosciences, Inc. filed with the SEC on 20 August 2026, one of 7 people that filing names.
William Chang is named as Director on the Form D that Ensysce Biosciences, Inc. filed with the SEC on 20 August 2026, one of 7 people that filing names.
Steve Martin is named as Director on the Form D that Ensysce Biosciences, Inc. filed with the SEC on 20 August 2026, one of 7 people that filing names.
Adam Levin is named as Director on the Form D that Ensysce Biosciences, Inc. filed with the SEC on 20 August 2026, one of 7 people that filing names.
David Humphrey is named as Executive Officer on the Form D that Ensysce Biosciences, Inc. filed with the SEC on 20 August 2026, one of 7 people that filing names.
James Morrison is named as Executive Officer and Director on the Form D that Ensysce Biosciences, Inc. filed with the SEC on 20 August 2026, one of 7 people that filing names.
7 people named on the filing — 3 holding an executive role and 4 as directors only.
Named as of the 2026-08-20 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Ensysce Biosciences, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ensysce Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ensysce Biosciences, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Ensysce Biosciences, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Ensysce Biosciences, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (ir.ensysce.com).
Each opens in a new tab, filled in for Ensysce Biosciences, Inc.. With no account yet, you sign up free and land on the result.
On these lists: San Diego raises, week of 2026-08-17 · Health care raises, week of 2026-08-17 · Health care raises in San Diego
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/ensysce-biosciences-inc-form-d-26000001